4D Molecular Therapeutics (FDMT) Competitors $3.10 +0.32 (+11.51%) Closing price 04:00 PM EasternExtended Trading$3.08 -0.02 (-0.81%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. GHRS, ALMS, QURE, BCYC, KURA, URGN, MGTX, IMTX, ARVN, and SIONShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include GH Research (GHRS), Alumis (ALMS), uniQure (QURE), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), UroGen Pharma (URGN), MeiraGTx (MGTX), Immatics (IMTX), Arvinas (ARVN), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. GH Research Alumis uniQure Bicycle Therapeutics Kura Oncology UroGen Pharma MeiraGTx Immatics Arvinas Sionna Therapeutics 4D Molecular Therapeutics (NASDAQ:FDMT) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Does the media prefer FDMT or GHRS? In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than GH Research. MarketBeat recorded 9 mentions for 4D Molecular Therapeutics and 1 mentions for GH Research. GH Research's average media sentiment score of 1.89 beat 4D Molecular Therapeutics' score of 0.73 indicating that GH Research is being referred to more favorably in the news media. Company Overall Sentiment 4D Molecular Therapeutics Positive GH Research Very Positive Which has preferable earnings & valuation, FDMT or GHRS? GH Research has lower revenue, but higher earnings than 4D Molecular Therapeutics. GH Research is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$37K3,691.65-$100.84M-$2.98-0.99GH ResearchN/AN/A-$35.59M-$0.75-12.12 Do analysts rate FDMT or GHRS? 4D Molecular Therapeutics currently has a consensus price target of $26.71, suggesting a potential upside of 805.57%. GH Research has a consensus price target of $30.86, suggesting a potential upside of 239.46%. Given 4D Molecular Therapeutics' higher possible upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, FDMT or GHRS? 4D Molecular Therapeutics has a beta of 2.89, suggesting that its share price is 189% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Does the MarketBeat Community favor FDMT or GHRS? 4D Molecular Therapeutics received 26 more outperform votes than GH Research when rated by MarketBeat users. However, 76.92% of users gave GH Research an outperform vote while only 65.88% of users gave 4D Molecular Therapeutics an outperform vote. CompanyUnderperformOutperform4D Molecular TherapeuticsOutperform Votes5665.88% Underperform Votes2934.12% GH ResearchOutperform Votes3076.92% Underperform Votes923.08% Do institutionals & insiders believe in FDMT or GHRS? 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 7.3% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is FDMT or GHRS more profitable? GH Research's return on equity of -20.29% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular TherapeuticsN/A -28.00% -26.16% GH Research N/A -20.29%-19.49% SummaryGH Research beats 4D Molecular Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$136.59M$2.89B$5.34B$7.60BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-1.0430.6721.7617.83Price / Sales3,691.65437.46378.0693.28Price / CashN/A168.6838.1534.64Price / Book0.413.476.414.00Net Income-$100.84M-$72.06M$3.20B$247.23M7 Day Performance17.53%8.70%6.59%7.42%1 Month Performance-28.22%-17.38%-8.57%-6.15%1 Year Performance-88.76%-29.70%10.11%-0.03% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.5782 of 5 stars$3.10+11.5%$26.71+761.8%-89.4%$143.54M$37,000.00-1.09120Positive NewsGap DownGHRSGH Research3.0821 of 5 stars$9.32-7.6%$30.86+231.1%-18.8%$484.90MN/A-11.8010Positive NewsHigh Trading VolumeALMSAlumis2.4159 of 5 stars$10.07+0.2%$26.00+158.2%N/A$475.53MN/A0.00N/AHigh Trading VolumeQUREuniQure2.1824 of 5 stars$8.76-2.2%$38.80+342.9%+91.8%$473.72M$27.12M-1.77500Short Interest ↑Gap DownBCYCBicycle Therapeutics1.9072 of 5 stars$6.75-2.0%$29.14+331.7%-68.3%$467.11M$35.28M-2.05240Gap DownKURAKura Oncology4.1524 of 5 stars$5.76-2.2%$25.50+342.7%-70.0%$465.15M$53.88M-2.44130URGNUroGen Pharma3.9232 of 5 stars$9.96-2.8%$38.20+283.5%-29.8%$459.10M$90.40M-3.16200MGTXMeiraGTx4.57 of 5 stars$5.75+1.2%$24.50+326.1%-1.4%$453.42M$33.28M-4.75300Gap DownHigh Trading VolumeIMTXImmatics2.357 of 5 stars$3.68+5.1%$16.67+352.9%-60.1%$439.23M$155.84M-5.58260Short Interest ↓Gap DownHigh Trading VolumeARVNArvinas3.7037 of 5 stars$6.37-2.9%$35.50+457.3%-79.6%$438.08M$263.40M-2.30420Short Interest ↓High Trading VolumeSIONSionna TherapeuticsN/A$9.73-2.4%$38.50+295.7%N/A$429.33MN/A0.0035Gap Down Remove Ads Related Companies and Tools Related Companies GHRS Alternatives ALMS Alternatives QURE Alternatives BCYC Alternatives KURA Alternatives URGN Alternatives MGTX Alternatives IMTX Alternatives ARVN Alternatives SION Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
